| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The non‑deuterated 7β‑hydroxycholesterol targets cellular organelles including mitochondria, lysosomes, and peroxisomes, inducing oxidative stress and apoptosis. It activates pro‑apoptotic pathways, including caspase‑3 and Bax, and disrupts membrane integrity. It also acts as a signaling molecule in inflammation and metabolic regulation. However, the deuterated analog has no biological target; it is used purely for analytical quantification.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, the unlabeled compound induces concentration‑dependent apoptosis in human umbilical vein endothelial cells (HUVECs) and other cell types. It increases ROS production and causes mitochondrial dysfunction. It also exhibits antitumor properties by promoting cancer cell death. The deuterated standard does not exhibit any of these activities; it is inert and serves only as a spike‑in control. |
| ln Vivo |
In vivo, increased plasma 7β‑hydroxycholesterol is associated with atherosclerosis and coronary heart disease mortality. It is used as a biomarker of oxidative stress. The labeled standard is used to quantify endogenous levels in patient samples. No therapeutic activity is attributed to the labeled compound.
|
| Enzyme Assay |
For analytical protocols, a typical method involves adding the deuterated standard (e.g., 10‑50 ng) to plasma or tissue homogenates. Lipids are extracted with chloroform/methanol (2:1), and the oxysterol fraction is purified by SPE. Derivatization (e.g., to trimethylsilyl ethers) may be performed for GC‑MS. For LC‑MS, the extract is directly injected onto a C18 column with mobile phase containing ammonium acetate. The labeled compound is monitored via MRM transitions (e.g., m/z 410 → 392 for the deuterated species).
|
| Cell Assay |
Not applicable for cellular assays. However, in cell culture experiments measuring 7β‑hydroxycholesterol, the labeled standard is added to cell lysates to correct for extraction efficiency. Cells are treated with test compounds, and after harvest, the internal standard is added before lipid extraction. The concentration of endogenous oxysterol is calculated from the analyte/IS peak area ratio.
|
| Animal Protocol |
In animal studies, the labeled standard is used to measure 7β‑hydroxycholesterol in plasma of atherosclerosis‑prone mice or rats. The animals are fed a high‑fat diet, and blood is collected at sacrifice. The standard is added to plasma prior to extraction and analysis. No administration of the labeled compound itself occurs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of the labeled standard are irrelevant. It is stable at ‑20°C as a solid and soluble in ethanol, DMF, and DMSO. It should be protected from light and oxygen. Its deuterium content ensures minimal overlap with the native compound.
|
| Toxicity/Toxicokinetics |
Toxicity is not applicable for the labeled standard; the unlabeled compound is cytotoxic. For handling the labeled material, standard precautions are sufficient. It is not intended for human use.
|
| References |
|
| Additional Infomation |
7β‑Hydroxycholesterol‑d7 is a key internal standard for oxysterol analysis in clinical and biomedical research. It helps to elucidate the role of oxysterols in cardiovascular and neurodegenerative diseases. It is available from specialized suppliers with high isotopic purity. The compound is often used in combination with other labeled sterols for comprehensive sterol profiling. Store at ‑80°C for long‑term stability.
|
| Molecular Formula |
C27H46O2
|
|---|---|
| Molecular Weight |
402.65294
|
| Exact Mass |
388.334
|
| CAS # |
349553-97-5
|
| PubChem CID |
3247057
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
503.4±38.0 °C at 760 mmHg
|
| Flash Point |
211.8±21.4 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.539
|
| LogP |
7.41
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
624
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
[2H]C([2H])([2H])C([2H])(CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C)C([2H])([2H])[2H]
|
| InChi Key |
OYXZMSRRJOYLLO-SVAMASIOSA-N
|
| InChi Code |
InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1/i1D3,2D3,17D
|
| Chemical Name |
(3S,7R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6,7,7,7-tetradeuterio-6-(trideuteriomethyl)heptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4835 mL | 12.4177 mL | 24.8355 mL | |
| 5 mM | 0.4967 mL | 2.4835 mL | 4.9671 mL | |
| 10 mM | 0.2484 mL | 1.2418 mL | 2.4835 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
